Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Rabeprazole
Drug ID BADD_D01898
Description Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.
Indications and Usage For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
Marketing Status Prescription; Discontinued
ATC Code A02BC04
DrugBank ID DB01129
KEGG ID D08463
MeSH ID D064750
PubChem ID 5029
TTD Drug ID D0KL4J
NDC Product Code 65162-724
Synonyms Rabeprazole | 2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)-1H-benzimidazole | Dexrabeprazole | E 3810 | E3810 | Pariet | Rabeprazole Sodium | Sodium, Rabeprazole | 1H-Benzimidazole, 2-(((4-(3-methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-, Sodium Salt | Aciphex | LY-307640 | LY 307640 | LY307640
Chemical Information
Molecular Formula C18H21N3O3S
CAS Registry Number 117976-89-3
SMILES CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCCCOC
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hyperlipidaemia14.08.03.001--
Urine analysis abnormal13.13.02.008--Not Available
Cystitis noninfective20.03.02.001--
Chronic kidney disease20.01.03.0170.001089%
Skin mass23.07.04.014--Not Available
Acute kidney injury20.01.03.0160.004176%
Drug-induced liver injury12.03.01.044; 09.01.07.0230.004176%Not Available
Lacrimal structural disorder06.06.04.013--Not Available
Hepatic cancer16.07.02.004; 09.04.02.008--Not Available
Hepatocellular carcinoma16.07.02.005; 09.04.02.0100.000311%Not Available
Medication residue present13.15.01.0320.002386%Not Available
Candida infection11.03.03.021--
Chronic gastritis11.07.01.016; 10.04.04.011; 07.08.02.0050.001790%Not Available
Richter's syndrome01.15.02.005; 16.28.02.0050.000311%Not Available
Gastric mucosal lesion07.11.03.0070.001790%Not Available
End stage renal disease20.01.03.0190.000311%Not Available
The 12th Page    First    Pre   12    Total 12 Pages